A series of promising truncated antibacterial tripeptides derived from lactoferricin has been prepared, and their in vitro metabolic stability in the main metabolic compartments, plasma, liver, kidney, stomach, duodenum, and brain, has been investigated for the first time. The potential stabilizing effect of truncation, C-terminal capping, and introduction of the bulky synthetic amino acid biphenylalanine is also investigated. The drug-like peptides displayed large differences in half-lives in the different matrixes ranging from 4.2 min in stomach and duodenum to 355.9 min in liver. Kinetic analysis of the metabolites revealed that several different degrading enzymes simultaneously target the different peptide bonds and that the outcome of the tested strategies to increase the stability is clearly enzyme-specific. Some of the metabolic enzymes even prefer the synthetic modifications incorporated over the natural counterparts. Collectively, it is shown that the necessary antibacterial pharmacophore generates compounds that are not only potent antibacterial peptides, but excellent substrates for the main degrading enzymes. All the amide bonds are thus rapidly targeted by different enzymes despite the short peptidic sequences of the tested compounds. Hence, our results illustrate that several structural changes are needed before these compounds can be considered for oral administration. Strategies to overcome such metabolic challenges are discussed.
come of the tested strategies to increase the stability is clearly enzyme-specific. Some of the metabolic enzymes even prefer the synthetic modifications incorporated over the natural counterparts. Collectively, it is shown that the necessary antibacterial pharmacophore generates compounds that are not only potent antibacterial peptides, but excellent substrates for the main degrading enzymes. All the amide bonds are thus rapidly targeted by different enzymes despite the short peptidic sequences of the tested compounds. Hence, our results illustrate that several structural changes are needed before these compounds can be considered for oral administration. Strategies to overcome such metabolic challenges are discussed.
Lactoferrin, an 80-kDa iron-binding glycoprotein, provides protection against a range of pathogens as a part of the innate immune system in many mammals (Masson et al., 1966; Bellamy et al., 1992) . The 25-residue fragment, lactoferricin (LfcinB), with improved antibacterial properties is formed upon gastric degradation at the N terminus (Bellamy et al., 1992) . The LfcinB fragment is cross-linked by a disulfide bridge between residues 3 and 20 and is rich in basic residues giving rise to a well defined secondary structure Vogel et al., 2002; Vorland et al., 1999) . The antibacterial activity of LfcinB of the bovine version is superior to homologs from other sources (Vorland et al., 1998) . It is noteworthy that reduction of the disulfide generates a linear peptide with similar activities that allowed the development of shorter synthetic derivatives with maintained properties (Bellamy et al., 1992) . Much of the work was initially focused on the 11-and 15-residue fragments LfcinB 4-14 and LfcinB 1-15 , yielding important insights into the structural requirements (Kang et al., 1996; Strøm et al., 2000 Strøm et al., , 2002 Nguyen et al., 2005) . Through these studies, it was shown that a combination of basicity and hydrophobicity, mainly in the form of arginine and tryptophan, is necessary for activity (Haug and Svendsen, 2001; Strøm et al., 2002 Strøm et al., , 2003 . Truncation, as a well known strategy to generate peptidomimetics with improved characteristics (Werle and Bernkop-Schnü rch, 2006) , provided active peptides with a minimal antibacterial motif for these peptides defined as two positive charges and two units of hydrophobic bulk, which allowed for the design of promising di-and tripeptides (Strøm et al., 2003; Haug et al., 2007) . Introduction of synthetic analogs to arginine and tryptophan in conjunction with C-and N-terminal modifications allows the construction of very efficient peptide-like compounds displaying minimal inhibitory concentrations in the low micromolar range against a range of pathogens, which makes these compounds potential antibiotic drug candidates in the struggle against the increasing threat from bacteria resistant to conventional antibiotics (Haug et al., 2007) . It is believed that these peptides will be less susceptible to resistance development because they are based on the innate immune system and on a bacterial target (cell membrane) that is less simple for the bacteria to modify via single mutations. A summary of the reported activities for a selection of truncated LfcinB derivatives is given in Table 1 .
General drawbacks associated with peptidic pharmaceuticals are cost of manufacture and, in the case of antimicrobial peptides, their narrow therapeutic index and metabolic instability (Leung et al., 2000; Werle and Bernkop-Schnü rch, 2006) . The cost issue can be circumvented by shorter peptides (Fig. 1) , which also yields a wider therapeutic index as shown by numerous studies where the hemolytic activity is compared with the antibacterial activity (Fernandez-Lopez et al., 2001; Haug et al., 2007; Chongsiriwatana et al., 2008) .
Stability is another important issue as oral bioavailability and sustained plasma presence are prerequisites for most new drug candidates, which in this case translates into significant resistance against proteolytic degradation (Leung et al., 2000) . Despite their small size, significant tryptic degradation was observed for these antimicrobial peptides, while several design principles allowed an improved peptide stability (Svenson et al., 2008) . Although survival in plasma is described in another recent study for three similar tripeptides incorporating ␤-(2,5,7-tri-tert-butylindol-3-yl)alanine as tryptophan replacement , no comprehensive study has yet been aimed at the systemic metabolic fate of this class of promising compounds. In articles from the De Spiegeleer group, the in vitro metabolic stability of the anorexigenic 23-residue peptide obestatin was described previously (Vergote et al., 2008; Van Dijck et al., 2009 ) using homogenates from the major compartments encountered in the systematic circulation. Both metabolite identity and kinetics were studied in a manner that yielded detailed information about the fate of the peptide. The methods used for establishing in vitro metabolic stability of obestatin in mice produced results that correlate well with in vivo results published previously (Pan et al., 2006; Vergote et al., 2008) . For a promising lead displaying high "drugability," such information is crucial from a drug design perspective. The current study is thus aimed at investigating the in vitro metabolic fate of LfcinB-derived antimicrobial peptides (including truncation, C-terminal capping, and incorporation of a synthetic amino acid derivative) in blood, liver, kidney, stomach, brain, and duodenum as major metabolic compartments. Kinetic analysis of the resulting metabolites is performed to provide further information about bonds susceptible to degradation, which can lead to subsequent synthetic work to optimize the stability of these compounds. ) , and L-arginyl-L-4,4Ј-biphenylalanyl-L-arginine benzylamide (RBipRNHBn) were synthesized and purified as described elsewhere (Svenson et al., 2009 ). Metabolites were either synthesized by use of standard Fmoc-chemistry or provided by Hanhong (Shanghai, China). All other reagents and solvents were of analytical grade or better. Organ Homogenates. Organ homogenates were prepared as described previously (Vergote et al., 2008) . In brief, kidneys, brain, liver, duodenum, and stomach were collected from male CD-1 mice. Each organ was cleaned and washed in ice-cold Krebs-Henseleit buffer, pH 7.4, before approximately 1.5 g was transferred to 50-ml rotor-stator disperser tubes. Thirty-six milliliters of ice-cold KrebsHenseleit buffer was added, and the organ was homogenized with an IKA Ultra-Turrax (IKA, Staufen, Germany) for 1 min. After sedimentation for 30 min at 5°C to remove the larger particles, 25 ml of the middle layer was taken as final homogenate, with aliquots stored at Ϫ35°C until further use. Before use, the protein content of each homogenate was determined by use of the Pierce Modified Lowry Protein Assay method to generate a stock solution with a protein concentration of 0.6 mg/ml by dilution with Krebs-Henseleit buffer. Plasma was collected according to previously described methods (Vergote et al., 2008) .
Materials and Methods

Chemicals
In Vitro Metabolic Stability. In vitro metabolic stability testing was determined with use of established procedures (Vergote et al., 2008) . In brief, 100 l of peptide dissolved in Krebs-Henseleit buffer, pH 7.4 (1 mg of peptide/ml), was added to 900 l of organ extract (500 l of homogenate ϩ 400 l of Krebs-Henseleit buffer, pH 7.4 ϭ 300 g of protein in total) or plasma, and kept at 37°C while shaking at 750 rpm in a Thermomixer comfort (Eppendorf, Hamburg, Germany). After 0, 5, 10, 15, 30, 45, 60 , and 90 min of incubation, 100-l samples were collected directly into tubes containing an equal volume of aqueous TFA (1% v/v). The enzymatic activity was terminated by additional heat inactivation at 95°C for 5 min after which the samples were cooled at 5°C for 30 min. Centrifugation at 20,000g for 5 min at 5°C yielded a clear supernatant ready for HPLC analysis. Blank control solutions were prepared accordingly but without added peptide (Fig. 2) . Control reference solutions, where the peptides were added after heat inactivation, were also prepared to confirm chemical stability and mass balance (Fig. 2) .
HPLC Analysis. The degradation of the peptides was studied by use of an HPLC system consisting of a Waters Alliance 2695 separation module, a Waters 2996 photodiode array detector, and a Waters 2475 multiwavelength fluorescence detector fitted with Empower 2 software for data handling (Waters, Milford, MA). Photodiode array detection was performed between 190 and 400 nm, with quantification at 280 nm (Trp) or 254 nm (biphenylalanine, or Bip), respectively. For fluorescence confirmatory detection, the excitation wavelength was set at 280 nm (Trp) or 230 nm (Bip) with emission recorded at 330 nm and 300 nm, respectively. For a standard HPLC run, a 10-l sample was injected and separated on an Alltima C 18 (250 ϫ 4.6 mm, 5-m particle size) column (Alltech Associates, Deerfield, IL) at 1 ml/min in an oven set at 30°C. Mixtures of water (0.1% TFA; v/v) and acetonitrile (0.1% TFA; v/v) were used to create appropriate gradients for separation of peptides and their metabolites. For identification confirmation, each metabolite was injected as well.
Antibacterial Activity. The antibacterial activity of peptides Ia, Ib, IIa, and IIb was tested against Staphylococcus aureus strain ATCC 25923 and Escherichia coli strain ATCC 25922. The studies were performed by Toslab AS (Tromsø, Norway) with use of standard methods.
Results
Metabolic Stability. The in vitro degradation of the LfcinB-derived peptides was followed by HPLC analysis as Figs. 2 and 3 , affording the metabolic halflives for the individual compounds. Initial studies to evaluate the effect of lactoferrin truncation on the metabolic stability were performed in mouse plasma, with Clf and LfcinB 4-14 peptides included, because they both display improved antibacterial properties, albeit still displaying several unwanted properties from a drug design perspective. Only peptides Ia, Ib, IIa, and IIb were analyzed in the other matrices as well, with the results summarized in Table 2 .
LfcinB 4-14 displayed the shortest half-life (15.6 min) of all the tested peptides in plasma. Clf on the other hand is the most resistant peptide tested (164.3 min) because of its cyclic nature, which is in agreement with other studies on cyclized peptides (Werle and Bernkop-Schnü rch, 2006) . The shorter peptides all display longer half-lives than LfcinB 4-14 does (between 30 and 100 min), indicating that truncation of these compounds undoubtedly has a positive effect on their metabolic stability, probably because of a lower number of interactions to the distant binding pockets surrounding the active sites of the major proteolytic enzymes. Incubation in duodenum extract yielded the shortest half-lives ranging from 4 to 11 min, similar to those obtained from the stomach incubation (4 -20 min). Thus, it is obvious that the main metabolic obstacle for these compounds is the gastrointestinal fluid. Survival in kidney extract was comparable with plasma with nearly identical half-lives for peptides Ia/Ib (73 and 78 min) and IIa/IIb (55 min). The longest half-lives were obtained from brain and liver homogenate. In brain, the peptides survived with a half-life of between 178 and 277 min displaying no significant variance. Peptides Ia/Ib were clearly more stable in liver extract (323 and 356 min, respectively) than IIa/IIb (113 and 106 min, respectively). Although detailed information could be obtained from the in vitro metabolism of the peptides, the interpretation toward the development of more promising candidates is not that straightforward.
Formation of Metabolites. HPLC coinjections of synthesized potential metabolites (Table 3) were performed to confirm the identity of the compounds formed during the degradation studies (Supplemental Data). Representative examples of the formation of different metabolites in the tested biological matrixes are shown in Fig. 4 .
Highly dependent on peptide sequence and biological matrix used, several different metabolites were produced. Some metabolites were rapidly formed and underwent further digestive processes generating secondary metabolites and complex mixtures of products. The major fragments formed are compiled in Table 4 .
Discussion
The metabolism and uptake of lactoferrin have been studied extensively over the years. Lactoferrin is mainly secretatory and not a serum protein, and thus it displays both short plasma half-life (10 min in adult rats) and a rapid clearance (Brock et al., 1976; Regoeczi et al., 1985; Kuwata et al., 2001; Troost et al., 2001 ). Its oral uptake in infants with immature intestines is established, but the absorption in adults remains controversial. A recent report (Fischer et al., 2007) described the distribution of lactoferrin to a number of organs after ingestion by adult mice, whereas a contradictory report showed that neither intact lactoferrin nor its functional fragments was detected in the portal blood of healthy adult rats after oral administration (Wakabayashi et al., 2004) . Significant improvements with regard to metabolic stability and more studies are clearly necessary to transform LfcinB-based compounds into clinically useful pharmaceuticals as is the goal for a number of recently established pharmaceutical companies.
The peptides in the present study are extremely truncated versions of lactoferrin with much improved pharmaceutical properties such as increased therapeutic index and antibacterial properties in conjunction with a rapid and affordable synthesis. Four peptides were selected as models representing the main strategies used to optimize the antibacterial effect (i.e., C-terminal amides and incorporation of synthetic amino acid derivatives). It should be noted that several other peptides have been prepared that display superior antibacterial effects (Strøm et al., 2003) . They represent peptides resembling in many ways the small peptides formed upon lactoferrin protein digestion in the gastrointestinal tract, and as such, they should display enhanced membrane permeability properties.
The introduction of the hydrophobic benzyl C-terminal amide modification, and likewise the bulky Bip side chain on the central amino acid, increases the antibacterial activity, and it was believed to be beneficial for the metabolic half-life. Although it was recently shown that a large hydrophobic central amino acid prevents efficient binding to trypsin (Svenson et al., 2008) , the increased stability effect of the Bip-containing peptides was only observed for stomach and duodenum and for plasma when combined with the N-terminal benzyl group. No significant difference was observed for the crude brain homogenate; however, for liver and kidney, a statistically significant destabilization was observed by the replacement of Trp by Bip. This enzymatic preference for a larger and less polar central amino acid than Trp was unexpected and illustrates how flexible (with regard to the size of side chains that fit) the binding pockets in the proteolytic active sites can be. In plasma, several different interaction modes seem to influence the degradation, because IIa was found to be the least stable molecule, whereas IIb (containing two large hydrophobic groups) is apparently less susceptible to proteolytic degradation than the two Trp-containing peptides.
To explain these differences, the kinetic profiles of the metabolites are used. Indeed, for plasma, brain, liver, and kidney, metabolization predominantly arises from the cleavage of the N-terminal arginine, probably arising from an aminopeptidase activity. This is in clear contrast to the metabolization in the stomach and duodenum homogenates where the peptide degradation is mainly taking part at the C-terminal side of the central amino acid. This cleavage pathway is consistent with proteases, such as pepsin, chymotrypsin, and trypsin.
A short overview of results obtained by Svenson et al. (2008) on the tryptic degradation of these antimicrobial peptides together with the currently obtained results and the minimal inhibitory concentrations found in the literature is given in Table 5 .
Although the absolute values reported here are different, the in vitro metabolic stability results involving stomach and duodenum homogenates display the same trend as seen for pure trypsin: peptide IIa with Bip as central amino acid, but without a C-terminal benzyl amide was found to be the most stable peptide versus trypsin. In this case, the C-terminal benzyl amide capping as in IIb is proposed to act as an additional residue, increasing the binding to the active site of trypsin. The significant difference observed in stability ratios between the tryptic treatment (i.e., Ϸ50) relative to tissues (i.e., Ϸ2) also illustrates how difficult it is to draw predictive conclusions regarding the systematic stability by solely looking at isolated enzymes.
In mouse plasma, the main primary metabolites formed are identical to those observed for liver and kidney homogenates. Nevertheless, the stabilizing effects are quite different, readily demonstrated by the absence of an effect by the C-terminal benzyl group in peptide incubation with liver and kidney homogenates. Hence, different proteases are demonstrated to target the same peptide bond. Although additional metabolic stability testing with specific protease inhibitors present could possibly yield more information on the identity of the active enzymes, this information may not be directly useful in the development of new peptidic derivatives, because they are faced with a number of diverse protease classes. It is clearly unfortunate from a metabolic point of view that the pharmacophore needed for an increased antibacterial activity also sets these peptide derivatives up for degradation by such an array of proteases despite their small size. The two cationic charges provided by arginine allow for two binding modes to the S1 pocket in trypsin where the one positioning the bulky central amino acid in S2 is clearly favored energetically both in this study and on studies performed with purified trypsin (Svenson et al., 2008) . Chymotrypsin is also involved in the metabolism of these peptides to quite an extent by hydrolyzing the bond between the central bulky amino acid and the C-terminal arginine yielding a characteristic RX-OH fragment. Chymotrypsin needs a bulky side chain in S1 and prefers a charged residue in S1Ј making these peptides excellent substrates. The same fragment is yielded upon pepsin degradation in the stomach. Pepsin cleaves amide bonds on either sides of a hydrophobic residue theoretically producing two different sets of metabolites (schematically displayed in Fig. 5 ) (Fruton, 1974) . The major fragment is nevertheless RX-OH, suggesting that the interactions in the S1 and S2 pockets are preferred over the three potential interactions with S1Ј, S2Ј, and S3Ј for this type of peptide substrate. The enzymes mentioned have all been endopeptidases, but it is apparent that exopeptidases also exert their action on the tested peptides. The free N-terminal arginine is vulnerable to aminopeptidase B, a metalloexopeptidase selectively removing the N-terminal basic residues arginine and lysine. Although not extensively investigated in humans, aminopeptidase B has been studied in other mammals and has recently been found in brain, plasma, liver, kidney, and gut in goats (Bogra et al., 2007) . The C-terminal arginine may also be targeted by carboxypeptidase B based on its substrate specificity. It is, however, unclear whether the C-terminal amide modification offers any additional stability in this case. The fragments yielded are the same as those of chymotrypsin, and because they are both found in fluid in the small intestine, it is impossible to distinguish between their activities without additional studies. Collectively, these five enzymes effectively digest the short peptides in a manner shown in Fig. 5 . Although the present study is not aimed at optimizing the metabolic stability, approaches are available to the medicinal chemist to increase the metabolic resistance against degradation as described recently (Bernkop-Schnü rch and Schmitz, 2007) . Acylation of the N-terminal amine, for example, may increase the stability toward aminopeptidase B. Earlier studies have shown, however, that such alterations increase the tryptic susceptibility by effectively transforming the tripeptide into a tetrapeptide (Svenson et al., 2008) illustrating the challenging complexity of the problem. An analogous effect is seen in the current study where the Bip side chain offers increased stability in stomach and duodenum while producing the oppo- site effect in liver and kidney. Following the trypsin and stomach/duodenum degradation results, linking the C terminus via a tertiary amide (in analogy to N-methylation) could yield molecules that are more appropriate for oral administration. If it is revealed that a specific enzyme is responsible for the bulk of the degradation, then inhibitors such as pepstatin, bestatin, leupeptin, and chymostatin can be coadministered to deal with the specific enzymes. Several problems can arise from this type of inhibitor coadministration though, and it is not a general solution acceptable in the pharmaceutical field (Bernkop-Schnü rch and Schmitz, 2007) . Maintaining the tripeptide sequence is a strategy to minimize the interactions with peripheral binding pockets on the main proteolytic enzymes, and a continued focus on arginine and tryptophan analogs may actually prove to be the simplest approach. The use of altered sequences may also prove effective as long as care is taken not to disrupt the amphipathic structure needed for activity (Svenson et al., 2009) . One must bear in mind that the structural alterations must not create peptides displaying insufficient bulk and cationic charge, because these properties also dictate the antibacterial properties. More work is clearly needed to establish which structural motifs optimize the stability without sacrificing a high antibacterial effect.
